60 DEGREES PHARMACEUTICALS, INC. — Form 8-K
Filed October 27, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
60 Degrees announced results from 5 completed patients in its expanded access babesiosis study (NCT06478641): all 5 (100%) reported clinical improvement and tested negative on conventional PCR; 4 of 5 (80%) were negative on highly sensitive blood-donor NAT testing performed 66–120 days post-treatment. The company claims a 3.6× higher retreatment-free rate (85.7% at ≥12 weeks) versus modeled 23.5% for conventional therapy, based on published case analysis. Two additional patients remain on treatment (total enrollment: 7). Company plans to unblind a separate randomized controlled hospital babesiosis trial in January 2027 and pursue FDA pre-sNDA discussions.
Why this rating
Early-stage, uncontrolled data in orphan disease supporting lead pipeline asset. At $3.3M market cap, positive clinical signals in babesiosis indication are material to valuation. However, small patient N (5 completed), no control arm, and unestablished surrogate endpoints create regulatory uncertainty.
Price action (we called it positive)
at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.